🇺🇸 FDA
Patent

US 10428159

Blocking monoclonal antibodies to AGR2 and its receptor C4.4A

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 10428159 (Blocking monoclonal antibodies to AGR2 and its receptor C4.4A) held by The Board of Regents of the University of Texas System expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K39/3955, A61K39/39558